<DOC>
	<DOCNO>NCT02887976</DOCNO>
	<brief_summary>An Open-label extension ( OLE ) , expand access study , assess long-term safety SoluMatrix™ Abiraterone Acetate 500mg ( 4 x 125 mg qd ) Methylprednisolone ( 4mg bid ) patient complete study number CHL-AA-201 .</brief_summary>
	<brief_title>Extension SoluMatrix TM Abiraterone Acetate Patients Who Completed Study Number CHL-AA-201</brief_title>
	<detailed_description>An Open-label extension ( OLE ) , expand access study , assess long-term safety SoluMatrix™ Abiraterone Acetate 500mg ( 4 x 125 mg qd ) Methylprednisolone ( 4mg bid ) patient complete study number CHL-AA-201 . An exploratory endpoint Improved safety switch Zytiga ( aberaterone Acetate 1000mg ( 4 x 250 mg qd ) SoluMatrix™ Abiraterone Acetate 500mg ( 4 x 125 mg qd ) also ascertained..</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Written inform consent obtain prior studyrelated procedure perform 2 . Previous , uninterrupted enrollment treatment trial number CHLAA201 . 1 . Progressive disease ascertain investigator use standardofcare evaluation . 2 . CHLAA201 D84 blood count follow : 1 . Absolute neutrophil count &gt; 1500/µL 2 . Platelets &gt; 100,000/µL 3 . Hemoglobin &gt; 9 g/dL 3 . CHLAA201 D84 chemistry value follow : 1 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 x Upper Limit Normal ( ULN ) 2 . Total bilirubin &lt; 1.5 x ULN 3 . Creatinine &lt; 1.5 x ULN 4 . Albumin &gt; 3.0 g/dL 5 . Potassium &gt; 3.5 mmol/L</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Castrate Resistant Prostate Cancer ( CRPC )</keyword>
	<keyword>metastatic</keyword>
	<keyword>castrate resistant</keyword>
</DOC>